Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005351 | 0.81 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL3002693 | 0.80 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL3010186 | 0.78 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL3009511 | 0.73 | KCNH2 (0.48) | KCNH2ALDH1A1 | |
| SCHEMBL3002742 | 0.73 | L3MBTL1 (0.47) | LMNATHRBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4975673 | 0.69 | SIGMAR1 (0.54) | KCNH2 | |
| SCHEMBL11860423 | 0.69 | SIGMAR1 (0.54) | KCNH2ALDH1A1 | |
| SCHEMBL3005291 | 0.67 | — | — | |
| SCHEMBL4978011 | 0.67 | SIGMAR1 (0.51) | — | |
| SCHEMBL3022523 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| WO-2008125349-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-23 | — | — | WO | disclosed |
| EP-1982987-A1 | Spiro-pyrano-pyrazole derivatives | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | SIGMAR1, TMEM97, OPRD1 | KCNH2 645/4885LMNA 2526/4885THRB 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.